IMMUNOGLOBULIN G1, ANTI-(HUMAN MESOTHELIN) (HUMAN MONOCLONAL MF-T-IGG1 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MF-T-IGG1 .LAMBDA.-CHAIN, DIMER, N6-(4-((4-(3-(BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)-2-((BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)METHYL)PROPYL)PHENYL)AMINO)-1,4-DIOXOBUTYL)-L-LYSINE COMPLEX WITH THORIUM-227TH
Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma
Bayerantibody_drug_conjugatePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atezolizumab M.D. Anderson Cancer Center | Phase 2 | CCC |
Dfn-15 David Bartlett | Phase 1/2 | CCC |
INTERFERON ALFA-2B David Bartlett | Phase 1/2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 1/2 | CCC |
trc102 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Rintatolimod David Bartlett | Phase 1/2 | CC |
Pegargiminase Polaris Group | Phase 1 | CC |
ct-95 Context Therapeutics Inc. | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN MESOTHELIN) (HUMAN MONOCLONAL MF-T-IGG1 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MF-T-IGG1 .LAMBDA.-CHAIN, DIMER, N6-(4-((4-(3-(BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)-2-((BIS(2-(((1,2-DIHYDRO-3-(HYDROXY-.KAPPA.O)-1-METHYL-2-(OXO-.KAPPA.O)-4-PYRIDINYL)CARBONYL)AMINO)ETHYL)AMINO)METHYL)PROPYL)PHENYL)AMINO)-1,4-DIOXOBUTYL)-L-LYSINE COMPLEX WITH THORIUM-227TH is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →